Front. Immunol.Frontiers in ImmunologyFront. Immunol.1664-3224Frontiers Media S.A.10.3389/fimmu.2024.1391710ImmunologyCorrectionCorrigendum: CD44 targeted delivery of oncolytic Newcastle disease virus encapsulated in thiolated chitosan for sustained release in cervical cancer: a targeted immunotherapy approachKousarKousain1*NaseerFaiza12AbduhMaisa Siddiq34AnjumSadia5AhmadTahir1*1Industrial Biotechnology, Atta-Ur-Rahman School of Applied Biosciences, National University of Sciences and Technology, Islamabad, Pakistan2Shifa College of Pharmaceutical Sciences, Shifa Tameer e Millat University, Islamabad, Pakistan3Immune Responses in Different Diseases Research Group, Department of Medical Laboratory Sciences, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, Saudi Arabia4Center of Excellence in Genomic Medicine Research, King Abdulaziz University, Jeddah, Saudi Arabia5Department of Biology, University of Hail, Hail, Saudi Arabia
Edited and Reviewed by: Mohammed Abu El-Magd, Kafrelsheikh University, Egypt
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
A corrigendum on CD44 targeted delivery of oncolytic Newcastle disease virus encapsulated in thiolated chitosan for sustained release in cervical cancer: a targeted immunotherapy approach by Kousar K, Naseer F, Abduh MS, Anjum S and Ahmad T (2023). Front. Immunol. 14:1175535. doi: 10.3389/fimmu.2023.1175535oncolytic Newcastle disease viruscervical cancergreen synthesissustained releaseCD44polymeric nanoparticlessection-in-acceptanceCancer Immunity and Immunotherapy
In the published article, there was an error in Figure 10 (C, D) TEM images of HA-ThCs-NDV NFs at 200nm and 500nm respectively and Figure 13 Change in morphology of treated HeLa cells with pure NDV and HA-ThCs-NDV in time and dose-dependent manner as published.
1- The image in Figure 10 (C, D) part highly resembles/overlaps with image of same nanoformulation from our own previous publication in Frontiers in Pharmacology, that occurred due to wrong tagging during data analysis (https://doi.org/10.3389/fphar.2022.1073004) - Figure 7B.
2- The image in Figure 13 of panel 10 ug/ml of pure NDV-24 hrs and HA-ThCs-NDV-24 hrs is incorrect as wrong slide was provided and the image highly resembles the image from our previous publication in Frontiers in Pharmacology, (https://doi.org/10.3389/fphar.2022.1073004) - and Figure 14a. The corrected Figures 10 and 13 and their captions appear below.
(A) SEM images showing spherical features of HA-ThCs-NDV NPs, (B) surface morphology of NFs.
Change in morphology of treated HeLa cells with pure NDV and HA-ThCs-NDV in time and dose-dependent manner.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. This error occurred as we were working on both studies (https://doi.org/10.3389/fphar.2022.1073004 and https://doi.org/10.3389/fimmu.2023.1175535) simultaneously and some of the data/slides were wrongly tagged by students working on the project.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.